[go: up one dir, main page]

AR065909A1 - Agentes terapeuticos 685 - Google Patents

Agentes terapeuticos 685

Info

Publication number
AR065909A1
AR065909A1 ARP080101362A ARP080101362A AR065909A1 AR 065909 A1 AR065909 A1 AR 065909A1 AR P080101362 A ARP080101362 A AR P080101362A AR P080101362 A ARP080101362 A AR P080101362A AR 065909 A1 AR065909 A1 AR 065909A1
Authority
AR
Argentina
Prior art keywords
alkyl group
substituted
hydroxy
fluorine
group
Prior art date
Application number
ARP080101362A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR065909A1 publication Critical patent/AR065909A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen ciertos compuestos 4,5,6,7-tetrahidropirrol[3,2-c]piridin-4-ona y 4,5- dihidropirroI[3,2-c]pidin-4-ona de formula 1, procedimientos para preparar dichos compuestos, y una formulacion farmacéutica. Compuestos utiles en el tratamiento dela obesidad, trastornos psiquiátricos y neurologicos. Reivindicacion 1: Un compuesto de formula 1 en la cual R1 representa un grupo alquilo C3-7 o un grupo alquilsulfonilo C3-7 y adicionalmente cuando R2 representa un grupo alquilo C1-4 sustituidocon hidroxi o con un grupo alcoxi C1-3, entonces R1 representa un grupo alquilo C3-7 sustituido con uno o más fluor, o un grupo alquilsulfonilo C3-7 sustituido con uno o más fluor; R2 representa un grupo alquilo C1-4 opcionalmente sustituido conhidroxi o un grupo alcoxi C1-3; ---- es un enlace adicional opcional entre las posiciones 6 y 7 pero solo cuando R2 representa un grupo alquilo C1-4 sustituido con hidroxi o con un grupo alcoxi C1-3; y R3 representa fluor o cloro; o una salfarmacéuticamente aceptable del mismo.
ARP080101362A 2007-04-03 2008-04-01 Agentes terapeuticos 685 AR065909A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90978507P 2007-04-03 2007-04-03

Publications (1)

Publication Number Publication Date
AR065909A1 true AR065909A1 (es) 2009-07-08

Family

ID=39592749

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101362A AR065909A1 (es) 2007-04-03 2008-04-01 Agentes terapeuticos 685

Country Status (3)

Country Link
AR (1) AR065909A1 (es)
UY (1) UY30996A1 (es)
WO (1) WO2008120000A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003027114A1 (en) * 2001-09-24 2003-04-03 Bayer Pharmaceuticals Corporation Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity
AR056560A1 (es) * 2005-10-06 2007-10-10 Astrazeneca Ab Pirrolopiridinonas como moduladores cb1

Also Published As

Publication number Publication date
WO2008120000A1 (en) 2008-10-09
UY30996A1 (es) 2008-11-28

Similar Documents

Publication Publication Date Title
ATE457979T1 (de) Als androgen-rezeptor-modulatoren verwendbare tetrahydrocarbazol-derivate
CY1108690T1 (el) Υποκατεστημενες ν-αρυλοπυρρολιδινες ως επιλεκτικοι διαμορφωτες υποδοχεα ανδρογονων
TW200612911A (en) Compounds for the treatment of inflammatory disorders
CR8644A (es) Compuestos de imidazol para el tratamiento de transtornos neurodegenerativos
TW200616620A (en) Compounds for the treatment of inflammatory disorders
TW200728307A (en) Novel spirochromanone derivatives
NZ593110A (en) pteridinone derivatives as MODULATORS OF TOLL-LIKE RECEPTORS
CO6382125A2 (es) Inhibidores de proteína quinasa
NO20083726L (no) Spiroindolinon derivater
PE20130402A1 (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
AR112532A2 (es) Compuestos de tetraciclina sustituidos con flúor en c7
PE20080130A1 (es) Benzoimidazol-2-il pirimidinas y pirazinas como moduladores del receptor h4 de histamina
PT2385053E (pt) Intermediários para a preparação de compostos bicíclicos condensados como inibidores mtor
NO20072831L (no) Imidazo[1,2-A]Pyridinforbindelser, sammensetninger, anvendelser og fremgangsmater relatert dertil
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
NO20076695L (no) Nye MCHR1-antagonister og deres anvendelse for behandling av MCHR1-medierte tilstander og forstyrrelser
PE20060937A1 (es) Derivados de sulfonilbencimidazol como agonistas del receptor cannabinoide 2 (cb2)
SV2006002473A (es) Forma cristalina ortorrombica del maleato de asenapina y su uso en el tratamiento de trastornos mentales ref. 2005.893 (806.671)
EA200700909A1 (ru) Азаиндолкарбоксамиды
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
ECSP055886A (es) Derivados de isoindolina
DE602005023197D1 (de) -muscarinrezeptors
EA200901474A1 (ru) Соли [4-(6-фтор-7-метиламино-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины в различных кристаллических формах и фармацевтические композиции на их основе
CR10830A (es) Compuestos para el tratamiento de trastornos cocleares y vestibulares
AR065909A1 (es) Agentes terapeuticos 685

Legal Events

Date Code Title Description
FB Suspension of granting procedure